Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28746933 | 1.00 | ADRB2 (0.61) | ADRB2TSHRHIF1AADRB1CYP1A2 | |
| SCHEMBL925593 | 0.82 | ADRB2 (0.41) | ADRB2TSHRHIF1AADRB1CYP1A2 | |
| SCHEMBL925596 | 0.82 | ADRB2 (0.41) | ADRB2TSHRHIF1AADRB1CYP1A2 | |
| SCHEMBL2831936 | 0.82 | ADRB2 (0.41) | ADRB2TSHRHIF1AADRB1CYP1A2 | |
| SCHEMBL13510949 | 0.81 | ADRB2 (0.41) | ADRB2HIF1AADRB1LMNACYP3A4 | |
| SCHEMBL27597363 | 0.81 | ADRB2 (0.41) | ADRB2HIF1AADRB1LMNACYP3A4 | |
| SCHEMBL15614743 | 0.81 | ADRB2 (0.41) | ADRB2HIF1AADRB1LMNACYP3A4 | |
| SCHEMBL17651818 | 0.81 | ADRB2 (0.38) | ADRB2TSHRCYP3A4 | |
| SCHEMBL828863 | 0.81 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL2569901 | 0.81 | ADRB2 (0.38) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110963929-B | Preparation method of salbutamol hydrochloride suitable for industrial production | 安徽恒星制药有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-110963929-A | Preparation method of salbutamol hydrochloride suitable for industrial production | 安徽恒星制药有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-6365756-B1 | KETALISATION BY CONDENSING WITH ACETONE; RECRYSTALLISATION; OPTICAL RESOLUTION OF THE MIXTURE OF ENANTIOMERS BY DISSOLVING IN A CHIRAL TARTARIC ACID DERIVATIVE; | FINE CHEMICAL CORPORATION LIMITED (ZA) | 2002-04-02 | — | — | US | claimed |
| EP-1056740-A1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ENRICHED (R)- OR (S)-ALBUTEROL | Fine Chemicals Corporation (Proprietary) Limited (ZA) | 2000-12-06 | — | — | EP | claimed |
| WO-1999042460-A9 | PROCESS FOR THE PRODUCTION OF OPTICALLY ENRICHED (R)- OR (S)-ALBUTEROL | FINE CHEMICALS CORP PROPRIETAR (ZA) | 2000-03-02 | — | — | WO | claimed |
| WO-1999042460-A1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ENRICHED (R)- OR (S)-ALBUTEROL | FINE CHEMICALS CORPORATION (PROPRIETARY) LIMITED (ZA) | 1999-08-26 | — | — | WO | claimed |
| CN-115611849-A | Refining method of levalbuterol intermediate | 祝瑞章 | 2023-01-17 | — | — | CN | disclosed |
| CN-110963929-B | Preparation method of salbutamol hydrochloride suitable for industrial production | 安徽恒星制药有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-110963929-A | Preparation method of salbutamol hydrochloride suitable for industrial production | 安徽恒星制药有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20100209508-A1 | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction | CORUS PHARMA, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209508-A1 | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction | CORUS PHARMA, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209508-A1 | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction | CORUS PHARMA, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-1999042460-A9 | PROCESS FOR THE PRODUCTION OF OPTICALLY ENRICHED (R)- OR (S)-ALBUTEROL | FINE CHEMICALS CORP PROPRIETAR (ZA) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209508-A1 | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885TSHR 2023/4885HIF1A 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.